http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Preoperative [^(18)F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer
Hyun Hoon Chung,Hyun Woo Kwon,Keon Wook Kang,Jae Weon Kim,Noh-Hyun Park,Yong-Sang Song,Soon-Beom Kang 대한부인종양학회 2012 Journal of Gynecologic Oncology Vol.23 No.1
Objective: To determine whether [^(18)F]FDG uptake on PET/CT imaging before surgical staging has prognostic significance in patients with epithelial ovarian cancer (EOC). Methods: Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUV_location ratio) on progression-free survival (PFS) was examined using Cox proportional hazards regression. Results: Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate analysis, high SUV_location ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [CI], 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed mullerian tumor compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUVlocation ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, mucinous, and malignant mixed mullerian tumor compared with endometrioid type) were significantly associated with recurrence. Patients were categorized into two groups according to SUVlocation ratio (<0.3934 vs. ≥0.3934), and the Kaplan-Meier survival graph showed a significant difference in PFS between the groups (p=0.0021; HR, 9.47, log-rank test). Conclusion: SUV distribution showed a significant association with recurrence in patients with EOC, and may be a useful predictor of recurrence. Objective: To determine whether [^(18)F]FDG uptake on PET/CT imaging before surgical staging has prognostic significance in patients with epithelial ovarian cancer (EOC). Methods: Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUV_location ratio) on progression-free survival (PFS) was examined using Cox proportional hazards regression. Results: Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate analysis, high SUV_location ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [CI], 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed mullerian tumor compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUVlocation ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, mucinous, and malignant mixed mullerian tumor compared with endometrioid type) were significantly associated with recurrence. Patients were categorized into two groups according to SUVlocation ratio (<0.3934 vs. ≥0.3934), and the Kaplan-Meier survival graph showed a significant difference in PFS between the groups (p=0.0021; HR, 9.47, log-rank test). Conclusion: SUV distribution showed a significant association with recurrence in patients with EOC, and may be a useful predictor of recurrence.
Wine drinking and epithelial ovarian cancer risk: a meta-analysis.
Kim, Hee Seung,Kim, Jae Weon,Shouten, Leo J,Larsson, Susanna C,Chung, Hyun Hoon,Kim, Yong Beom,Ju, Woong,Park, Noh Hyun,Song, Yong Sang,Kim, Seung Cheol,Kang, Soon-Beom Korean society of gynecologic oncology and colposc 2010 Journal of Gynecologic Oncology Vol.21 No.2
<P>Wine has been the focus in the prevention of epithelial ovarian cancer (EOC) development because resveratrol abundant in wine has anti-carcinogenic properties. However, epidemiologic results have been heterogenous in the chemopreventive effect of wine on the development of EOC. Thus, we performed a meta-analysis for comparing EOC risk between wine and never drinkers using previous related studies.</P>
Kim, Hee Seung,Kim, Jae Weon,Wu, Hong Gyun,Chung, Hyun Hoon,Park, Noh Hyun,Song, Yong Sang,Kang, Soon Beom,Lee, Hyo Pyo Blackwell Publishing Asia 2010 JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH -TO Vol.36 No.3
<P><B>Abstract</B></P><P><B>Aim: </B> We sought to compare survival and toxicity between paclitaxel/carboplatin (TC) and doxorubicin/cisplatin (AP) for concurrent chemoradiation (CCR) in intermediate‐ or high‐risk endometrioid endometrial cancer.</P><P><B>Methods: </B> The clinical data of 40 patients with intermediate‐ (FIGO stage IC‐IIB, <I>n</I> = 12) or high‐risk endometrioid endometrial cancer (FIGO stage IIIA‐IVA, <I>n</I> = 28) were reviewed retrospectively between March 2000 and December 2007, who were treated with TC (<I>n</I> = 23, group 1) or AP (<I>n</I> = 17, group 2) for CCR after surgery.</P><P><B>Results: </B> Progression‐free survival (PFS) and overall survival (OS) were not different between groups 1 and 2 (median PFS and OS; 35 vs 24 and 76 vs 39 months, respectively, <I>P</I> > 0.05). However, ≥6 cycles of chemotherapy improved PFS compared with 3–5 cycles of chemotherapy (51 vs 21 months, <I>P</I> = 0.04), suggesting that ≥6 cycles of chemotherapy was an independent prognostic factor improving PFS (adjusted HR, 0.27; 95% CI, 0.08 to 0.91; <I>P</I> = 0.04). Grade 3 or 4 hematological and non‐hematological, especially, gastrointestinal, toxicities related with chemotherapy during CCR were more common in group 2 than in group 1, whereas there was no difference in grade 3 or 4 late complication by CCR between the 2 groups.</P><P><B>Conclusion: </B> These findings suggest that TC may have comparable efficacy to AP for CCR with lesser toxicity, and ≥6 cycles of chemotherapy may be more beneficial than 3–5 cycles of chemotherapy in intermediate‐ or high‐risk endometrioid endometrial cancer. However, large‐scale randomized controlled trials are needed to support these results.</P>
Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer
Hoon Chung, Hyun,Kim, Jae Weon,Kang, Keon Wook,Park, Noh-Hyun,Song, Yong-Sang,Chung, June-Key,Kang, Soon-Beom Elsevier 2012 European journal of radiology Vol.81 No.8
<P>To evaluate the efficacy of post-treatment positron emission tomography (PET)/computed tomography (CT) for identification of tumor recurrence, and to determine whether [(18)F]fluorodeoxyglucose (FDG) uptake measured as the maximum standardized uptake value (SUV(max)) has predictive role regarding survival in patients with uterine cervical cancer.</P>
Kim, Hee Seung,Park, Noh Hyun,Kang, Sokbom,Seo, Sang-Soo,Chung, Hyun Hoon,Kim, Jae Weon,Song, Yong Sang,Kang, Soon-Beom Blackwell Publishing Asia 2010 The Journal of obstetrics and gynaecology research Vol.36 No.1
<P>Abstract</P><P>Aim: </P><P>To compare the efficacy and toxicity between topotecan- and belotecan-based chemotherapies in recurrent epithelial ovarian cancer (EOC).</P><P>Methods: </P><P>The clinical data of 80 patients treated with topotecan- (<I>n</I> = 45) or belotecan- (<I>n</I> = 35) based chemotherapy as at least a second-line chemotherapy were reviewed retrospectively between July 2001 and December 2007. Response was evaluated using the Response Evaluation Criteria in Solid Tumours (RECIST) and serum CA-125 levels. Hematological toxicity was examined according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. Time to progressive disease (TTPD), chemotherapy-specific survival (CSS) and overall survival (OS) according to the 2 chemotherapies were evaluated by the Kaplan-Meier analysis with the log-rank test.</P><P>Results: </P><P>Overall response rate (ORR) was 24.4% in patients treated with topotecan-based chemotherapy, while it was 45.7% in those treated with belotecan-based chemotherapy (<I>P</I> = 0.046). Moreover, ORR was higher in platinum-sensitive patients treated with belotecan-based chemotherapy (58.8%) than those treated with topotecan-based chemotherapy (22.2%) (<I>P</I> = 0.041) although it was not significantly different in platinum-resistant patients (<I>P</I> = 0.471). Grade 3 or 4 anemia, neutropenia and thrombocytopenia developed in 14.8% vs 3.6%, 43.1% vs 55.6%, and 20.0% vs 12.8% of cycles in topotecan- and belotecan-based chemotherapies, respectively (<I>P</I> < 0.05). There were no significant difference in survival between the 2 chemotherapies.</P><P>Conclusions: </P><P>In our experience, belotecan-based chemotherapy seemed to be efficient with acceptable toxicity, compared to topotecan-based chemotherapy in recurrent EOC. However, randomized controlled trials are required for the comparison of the efficacy and toxicity between topotecan- and belotecan-based chemotherapies in recurrent EOC.</P>